- Joined
- Aug 19, 2003
- Messages
- 7,754
- Reaction score
- 70
- Points
- 4,756
Advertisement - Members don't see this ad
I thought for sure the FDA would make a decision based on scientific evidence. Apperently, this is not the case. Holding public comments is basically inviting politics into the matter. What a bunch of bullshi+!
FDA Defers Decision on Plan B Over-the-Counter Application
Agency to Initiate Rulemaking Proceeding on 'Dual Label' Concept
WOODCLIFF LAKE, N.J., Aug. 26 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that it has received a letter from the U.S. Food and Drug Administration (FDA) concerning the Company's Supplemental New Drug Application (sNDA) seeking Over-the-Counter (OTC) status for its Plan B(R) emergency contraceptive product. The letter states that "the Center for Drug Evaluation and Research ... has completed its review of this application, as amended, and has concluded that the available scientific data are sufficient to support the safe use of Plan B as an OTC product ... for women who are 17 years of age and older." Notwithstanding this clear scientific determination, the FDA has delayed any action on the application. Instead, the FDA informed the Company that it intends to seek public comment on issues related to the approval of a product that has OTC status for patients 17 and older and prescription status for patients 16 and under. In its communication with the Company, the FDA did not commit to any timetable for initiating or concluding the rulemaking proceeding.
"We are disappointed that the FDA did not approve our application. In our submission to the FDA we provided a detailed legal analysis supporting approval of a dual label product and continue to believe that a dual label status can and should be approved for Plan B," said Bruce L. Downey, Barr's Chairman and CEO. "While we believe that a delay is not justified, we will use the opportunity presented by the FDA proceedings to continue to press for approval of Plan B as an OTC/Rx Product."
FDA Defers Decision on Plan B Over-the-Counter Application
Agency to Initiate Rulemaking Proceeding on 'Dual Label' Concept
WOODCLIFF LAKE, N.J., Aug. 26 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that it has received a letter from the U.S. Food and Drug Administration (FDA) concerning the Company's Supplemental New Drug Application (sNDA) seeking Over-the-Counter (OTC) status for its Plan B(R) emergency contraceptive product. The letter states that "the Center for Drug Evaluation and Research ... has completed its review of this application, as amended, and has concluded that the available scientific data are sufficient to support the safe use of Plan B as an OTC product ... for women who are 17 years of age and older." Notwithstanding this clear scientific determination, the FDA has delayed any action on the application. Instead, the FDA informed the Company that it intends to seek public comment on issues related to the approval of a product that has OTC status for patients 17 and older and prescription status for patients 16 and under. In its communication with the Company, the FDA did not commit to any timetable for initiating or concluding the rulemaking proceeding.
"We are disappointed that the FDA did not approve our application. In our submission to the FDA we provided a detailed legal analysis supporting approval of a dual label product and continue to believe that a dual label status can and should be approved for Plan B," said Bruce L. Downey, Barr's Chairman and CEO. "While we believe that a delay is not justified, we will use the opportunity presented by the FDA proceedings to continue to press for approval of Plan B as an OTC/Rx Product."